Bionano Q2 revenue rises 21% to $8.2 million; net loss widens to $7.4 million
Bionano Genomics reported second quarter 2026 revenue of $8.2 million, up 21% from $6.7 million a year earlier, and a net loss of $7.4 million, up from $6.9 million. The company also gave revenue guidance of $8.2 million to $8.6 million for the third quarter and $31 million to $33 million for full year 2026, and said it fully retired its senior secured convertible debentures during the quarter.
Key points
- Q2 2026 total revenue was $8.2 million, up 21% from $6.7 million; consumables revenue rose 31% to $4.3 million.
- Net loss for the quarter was $7.4 million, compared with $6.9 million in Q2 2025.
- Q3 2026 revenue guidance is $8.2 million to $8.6 million; full year 2026 revenue guidance is $31 million to $33 million.
- All outstanding senior secured convertible debentures were retired, eliminating secured debt and releasing liens on company assets.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.